# RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer

> **NCT05578287** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 29 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Anti-HER2 ADC

## Key facts

- **NCT ID:** NCT05578287
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-18
- **Primary completion:** 2024-12-15
- **Final completion:** 2025-12-25
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578287, "RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05578287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*